A Phase 3, Open-label, Rollover Study to Evaluate the Safety of Long-Term Treatment with Lumacaftor in Combination with Ivacaftor in Subjects Aged 12 Years and Older with Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation